<SEC-DOCUMENT>0001104659-20-034074.txt : 20200316
<SEC-HEADER>0001104659-20-034074.hdr.sgml : 20200316
<ACCEPTANCE-DATETIME>20200316161705
ACCESSION NUMBER:		0001104659-20-034074
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200316
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200316
DATE AS OF CHANGE:		20200316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		20717342

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2012847d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, D. C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
March 16, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>PRECIPIO,
INC.</B></FONT><B><BR>
</B><I>(Exact Name of Registrant as Specified in Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware<BR>
</B><I>(State of Incorporation)</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>001-36439<BR>
</B><I>(Commission File Number)</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>91-1789357<BR>
</B><I>(I.R.S. Employer Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>4 Science Park, New Haven, CT 06511</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Address of principal executive offices)
(Zip Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(203) 787-7888&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Registrant's telephone number, including
area code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Not Applicable<BR>
</B><I>(Former name, former address and former fiscal year, if changed since last report date)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding: 1.5pt; font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center; width: 33%">Title of each class</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center; width: 34%">Ticker symbol(s)</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center; width: 33%">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">Common Stock, $0.01 par value per share</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">PRPO</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">The Nasdaq Stock Market LLC</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><B>Item 7.01</B></TD><TD><B>Regulation FD Disclosure</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 16 Precipio, Inc. (the &ldquo;<U>Company</U>&rdquo;)
issued a press release in connection with the company&rsquo;s completion of a transaction relating to Oncometrix Hematopathology
division. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Current Report on Form 8-K, including
Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that
Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated
by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby
shall not be deemed an admission as to the materiality of any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <A HREF="tm2012847d1_ex99-1.htm">99.1 Precipio Inc. Press Release March 16, 2020</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>PRECIPIO, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 40%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 10%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 5%; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; width: 45%; border-bottom: black 1pt solid; text-indent: 0">/s/ Ilan Danieli </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Ilan Danieli</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&#9;March 16, 2020 &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2012847d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Precipio Completes the Transaction with
Poplar Healthcare&rsquo;s Oncometrix Hematopathology Division </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Customer base and sales team transition
to Precipio, Doubling Revenues</I></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW HAVEN, CT, (March 16, 2020) &ndash;
</B>Specialty diagnostics company <FONT STYLE="color: #1155CC"><U>Precipio, Inc</U>.</FONT> (<FONT STYLE="color: #1155CC"><U>NASDAQ:
PRPO</U></FONT>), announced today that it has completed the non-cash transaction of the transition of Oncometrix&rsquo;s customer
base, as discussed in Precipio&rsquo;s recent <FONT STYLE="color: blue"><U>announcement</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As stated previously, the transaction with
Poplar involves no upfront exchange of cash or equity in consideration, providing for a non-dilutive transaction. Assuming a continued
successful implementation of the transition and no disproportionate impact from COVID-19, management anticipates that the transaction
will impact revenue growth, gross margin and cash flow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B><U>Projected Revenues more than Double</U></B>. This transaction and Precipio&rsquo;s current
growth initiatives have increased revenue projections for the 2020 Hemepath diagnostic business to more than $6.5M, representing
more than 160% increase (or 2.6x) when compared to the 2019 unaudited pathology services revenues of $2.5M.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B><U>Projected Gross Margin more than Doubles</U></B>. As a highly scalable, volume-driven business,
this growth will have a material impact on Precipio&rsquo;s laboratory business gross margin. With minimal capital equipment expenditures
required to process the increase in volume, we anticipate Hemepath product line gross margins to improve from the current level
of 16% to 34%. Furthermore we project incremental Hemepath business above $6.5M to reach estimated margins of 50%.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><B><U>Projected Cash Burn Reduced by more than $800K</U></B>. While Precipio has absorbed the three
additional sales representatives from Oncometrix, as well as several additional hires in laboratory operations to handle the volume
increase, it is anticipated that the net cash impact due to this transaction will be an estimated reduction of $800,000 in cash
burn on an annualized basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are delighted to complete this
transaction, partner with Precipio for the hematopathology business, enabling us to focus on our other core businesses&rdquo;,
said James Sweeney, CEO of Poplar Healthcare. &ldquo;We look forward to continued collaboration with Precipio in other areas of
our partnership&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;While every absorption of a business
is challenging, this transaction is an exact fit with current Precipio operations. I am confident in our team&rsquo;s quick execution
of this strategic initiative, and believe it will have a substantial impact on the company&rdquo;, said Ilan Danieli, Precipio
CEO. &ldquo;We are excited to work with the Oncometrix team and continue to provide their customers and patients with outstanding
quality and service; we too look forward to a continued fruitful partnership with the Poplar team&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Precipio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Precipio has
built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed
within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through
its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the
Yale School of Medicine, Harvard&rsquo;s Dana-Farber Cancer Institute and the University of Pennsylvania, Precipio offers a new
standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit <FONT STYLE="color: #1155CC"><U>www.precipiodx.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain statements
in this press release constitute &ldquo;forward-looking statements,&rdquo; within the meaning of federal securities laws, including
statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and
prospects and other statements containing the words &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; and similar expressions,
constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company&rsquo;s
actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.
Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements
include the known risks, uncertainties and other factors described in the Company&rsquo;s definitive proxy statement filed on May
29, 2018, the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and on the Annual Report on
Form 10-K for the year ended December 31, 2018 as well as the Company&rsquo;s prior filings and from time to time in the Company&rsquo;s
subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the
actual results, events and performance to differ materially from those referred to in such statements. All information in this
press release is as of the date of the release and the Company does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC"><B><U>investors@precipiodx.com</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">+1-203-787-7888
Ext. 523</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( 6\# 2(  A$! Q$!_\0
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M\<;L=JX7R?BMC_CYT/I_=/\ A7H8P.,4M3&5N@VCSLQ?%;G_ $C0^_\ "?\
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M%Q-;MPR'Z$=/>NBE4;]V:LSLHUI/W:BM+\S9(!ZUDZ_X>L]?L6@N4 =1^ZF
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M_ -2EKNKM\3-2@\.Z&LC:1%,LM_?,NU6 / 7^G<GM@5Z9=1K!I,\:#:B0,%
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MG7)+')Z.*V/[;^)W_0L:7_W_ /\ [.KE&\F[H2>AZ'17GG]M?$[_ *%C3/\
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M7LB*$55   &  ,8%8XJNG[D?F72AU8ZC HHKA-@Z4444 %%%% !UHP!THHH
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A,!L#ITKH8]2L7M?M"7430;MN]6RN?3-%%:2A8E2UL?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
